STAT3 and myeloid sarcoma: Additional genes of interest were highlighted by their centrality within top gene modules: GRB2, JAK2, MAPK1 and STAT3. Given that the central genes HDAC1 and RELA genes are currently drug targets of FDA approved MS treatment, this suggests other central genes identified may be promising drug targets for future investigation.